Abstract:Genetic engineering is one of the most advanced technologies in the world and can bring vast profits to developers by patenting resultant achievements. But genetic engineering must be based on original genetic materials. For obtaining such materials, developers travel around the world, especially to genetically rich areas in developing countries, to prospect for valuable genetic resources and bring back for research and patent derivate products. However a lot of disputes have arisen from such patents, such as the Enola patent dispute on Mexican traditional crop mayocoba bean and the patent dispute on sacred plant Ayahuasca between people and one U.S. Company. Indigenous people, who live in the origin areas of genetic resources for a long history, have established traditional and cultural genuine relation with some living species. These disputes revealed that some genetic engineering exploitation and patents based on certain species may be severely offensive against indigenous peoples spiritual, religious, or cultural traditions. Although genetic engineering achievements patentability has been argued for a long time, the TRIPs Agreement requirement and the worlds legislation trend, either in developed countries such as the U.S., European Union or in developing countries such as China, have indicated that genetic engineering products and processes are legitimately patentable. But some loophole exists in the patent acquisition procedure of current legislation, which allows such offensive patents to be granted. To prevent such offensive patents, one prior consents solution is proposed in this article, which requires genetic engineering developers to obtain prior consents from origin countries of genetic resources before they exploit these resources and patent derivate achievements. This solution is based on the Convention on Biological Diversity, which affirmed countrys sovereignty over their genetic resources and allowed countries to regulate and manage genetic resources in their territory. The Convention on Biological Diversity does not conflict with IPR legislation, in particular the TRIPs Agreement and the obligations under both treaties should be respected. The implementation of this proposed solution is based on the establishment of national genetic resources authority, which generally manages its countrys genetic resources and works as indigenous peoples representative with the authorization of state government. This solution should be implemented in three levels: domestically, transnationally and globally. Therefore, offensive genetic engineering patents could be prevented both by such authoritys examination and granting prior consents before developers access to genetic resources and by national patent administrations examination on prior consents proof from origin countrys authority before granting patents.

A Feasible Pathway for Open Access to Human Embryonic Stem Cell Patents—With China's Open License for Patent as the Entry Point

14-Day Limit of Human Embryo Research: Moral Issues in the Patent Law in China

Interplay of the Amendments to Chinese Scientific and Technological Progress Law and Patent Law

The study of current stem cell patent technology

Technology Development Through Pooling ARV Drug Patents: A Vision from China.

The Evolution of China's IPR System and Its Impact on the Patenting Behaviours and Strategies of Multinationals in China.

The commercialization of human stem cells: ethical and policy issues

Promoting the exploration and research of hospital patent transformation through multiple channels

Promoting Nursing Patents and Eliminating Barriers to the Implementation of Nursing Intellectual Property Rights

Access to stem cells and data: persons, property rights, and scientific progress

The International Protection of Intellectual Property Rights and the Challenges China is Confronted With

Discussion on emergency transfer of hospital service invention patent during COVID-19 pandemic period

Managing intellectual property and technology commercialization: Comparison and analysis of practices, success stories and lessons learned from public research universities in developing Asia

A concise framework to facilitate open COVID pledge of non-disclosed technologies: In terms of non-disclosed patent applications and trade secrets

Regulatory Oversight of Cell Therapy in China: Government's Efforts in Patient Access and Therapeutic Innovation.

Patenting Human Genes: Chinese Academic Articles’ Portrayal of Gene Patents

Analysis on the Dilemma and Strategy of Open Access in China

Patent Regime Shift and Firm Innovation: Evidence from the Second Amendment to China’s Patent Law

Strategic Use of the Second-Tier Patent System for Short Life-Cycle Technologies — Evidence from Parallel Filings in China

TRIPS-plus and Access to Medicines in China.

Prior Consents: Preventing Offensive Genetic Engineering Patents Against Indigenous People's Rights